Mumbai-based pharmaceutical and biotechnology company Wockhardt says that it will launch its generic version of GSK’s Flonase fluticasone nasal spray in the US immediately after having received approval from the US FDA. The company will manufacture the 50 mcg dose nasal spray for the treatment of allergic rhinitis at its facility in Morton Grove, IL. No other nasal sprays appear on Wockhardt’s US product list.
Wockhardt Chairman Habil Khorakiwala commented, “Wockhardt is amongst the few companies to have an approval for Fluticasone nasal spray. We have always endeavoured to develop and market products based on challenging technologies and this approval of a nasal spray is another step in that direction. The product involved development of complex precisely controlled formulation as well as the device for the spray. The regulatory approval also required us to conduct clinical trials.”
Read the Wockhardt press release.
